Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.
Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL Jr, Gelber RD, Hortobagyi GN, Albain KS; POEMS/S0230 Investigators. Moore HC, et al. Among authors: lombard jm. N Engl J Med. 2015 Mar 5;372(10):923-32. doi: 10.1056/NEJMoa1413204. N Engl J Med. 2015. PMID: 25738668 Free PMC article. Clinical Trial.
Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230.
Moore HCF, Unger JM, Phillips KA, Boyle F, Hitre E, Moseley A, Porter DJ, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow JR, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian LM, Meyskens FL, Gelber RD, Hortobagyi GN, Albain KS. Moore HCF, et al. Among authors: lombard jm. J Natl Cancer Inst. 2019 Feb 1;111(2):210-213. doi: 10.1093/jnci/djy185. J Natl Cancer Inst. 2019. PMID: 30371800 Free PMC article.
Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Saura C, Hlauschek D, Oliveira M, Zardavas D, Jallitsch-Halper A, de la Peña L, Nuciforo P, Ballestrero A, Dubsky P, Lombard JM, Vuylsteke P, Castaneda CA, Colleoni M, Santos Borges G, Ciruelos E, Fornier M, Boer K, Bardia A, Wilson TR, Stout TJ, Hsu JY, Shi Y, Piccart M, Gnant M, Baselga J, de Azambuja E. Saura C, et al. Among authors: lombard jm. Lancet Oncol. 2019 Sep;20(9):1226-1238. doi: 10.1016/S1470-2045(19)30334-1. Epub 2019 Aug 8. Lancet Oncol. 2019. PMID: 31402321 Clinical Trial.
Impact of prior (neo)adjuvant trastuzumab (NAT) exposure on the efficacy of HER2-targeted therapy for metastatic breast cancer.
Kanjanapan Y, Lok SW, Gibbs P, De Boer R, Yeo B, Greenberg S, Barnett F, Knott L, Richardson G, Wong R, Nottage M, Collins IM, Torres J, Lombard J, Johns J, Harold M, Malik L. Kanjanapan Y, et al. Breast Cancer Res Treat. 2020 Nov;184(1):87-95. doi: 10.1007/s10549-020-05825-w. Epub 2020 Aug 10. Breast Cancer Res Treat. 2020. PMID: 32779037
Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 + /HR + metastatic breast cancer.
Loft M, Lok SW, De Boer R, Malik L, Greenberg S, Yeo B, Anton A, Nottage M, Wong V, Nott L, Collins IM, Torres J, Barnett F, Lombard JM, Gibbs P, Gately L. Loft M, et al. Among authors: lombard jm. Breast Cancer Res Treat. 2023 Feb;198(1):67-74. doi: 10.1007/s10549-022-06856-1. Epub 2023 Jan 9. Breast Cancer Res Treat. 2023. PMID: 36624321
32 results